Tridek-One Closes A €16M Financing Round Led By Pureos Bioventures
09/15/22, 8:22 AM
Location
parisMoney raised
€16 million
Industry
biotechnology
health care
Tridek-One SAS, a biotech start-up specialised in the research and development of CD31 agonists to restore the immune balance, has closed a €16 million ($16.1m) financing round led by the Swiss VC Pureos Bioventures.
Company Info
Location
paris, ile de france, france
Additional Info
Founded in 2018 by Dr. Giuseppina Caligiuri and Professor Antonino Nicoletti, researchers in INSERM Unit 1148, located at Bichat Hospital in Paris, with the support of the funds Advent France Biotechnology, Tridek-One is developing a novel CD31 agonist approach to modulate immune activation and so provide a new way to manage inflammatory conditions. Tridek-One has announced a 3M€ funding supported by two venture funds, Advent France Biotechnology and Advent Life Sciences (UK).